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Abstract
Background: Neoadjuvant (chemo-)radiation has proven to improve local control compared to surgery alone, but
this improvement did not translate into better overall or disease-specific survival. The addition of oxaliplatin to
fluoropyrimidine-based neoadjuvant chemoradiotherapy holds the potential of positively affecting survival in this
context since it has been proven effective in the palliative and adjuvant setting of colorectal cancer. Thus, the
objective of this systematic review is to assess the efficacy, safety, and quality of life resulting from adding a
platinum derivative to neoadjuvant single-agent fluoropyrimidine-based chemoradiotherapy in patients with Union
for International Cancer Control stage II and III rectal cancer.
Methods: MEDLINE, Web of Science, and Cochrane Central Register of Controlled Trials will be systematically
searched to identify all randomized controlled trials comparing single-agent fluoropyrimidine-based
chemoradiotherapy to combined neoadjuvant therapy including a platinum derivative. Predefined data on trial
design, quality, patient characteristics, and endpoints will be extracted. Quality of included trials will be assessed
according to the Cochrane Risk of Bias Tool, and the GRADE recommendations will be applied to judge the quality
of the resulting evidence. The main outcome parameter will be survival, but also treatment toxicity, perioperative
morbidity, and quality of life will be assessed.
Discussion: The findings of this systematic review and meta-analysis will provide novel insights into the efficacy
and safety of combined neoadjuvant chemoradiotherapy including a platinum derivative and may form a basis for
future clinical decision-making, guideline evaluation, and research prioritization.
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Background
Colorectal cancer is one of the most common malig-
nant diseases in industrialized nations, with an esti-
mated number of > 135,000 new cases and > 50,000
deaths in the USA for the year 2017. Thus, it is one of
the three most common causes of cancer deaths in
adults of both sexes [1, 2]. Furthermore, colorectal can-
cer has a tremendous economic impact accounting for
approximately € 6 billion costs due to lost productivity
in Europe 2008, because of cancer-related premature
mortality [3].
About one third of all colorectal carcinomas are located
in the rectum and therefore require specific treatment
algorithms [1, 2]. The routine use of total mesorectal
excision has served to increase survival and reduce the
rates of local recurrence in this patient population [4, 5].
Furthermore, international and national guidelines on
colorectal cancer recommend neoadjuvant therapy con-
sisting of either short-term radiation (5 × 5 Gy) or com-
bined chemoradiotherapy (usually with a total of 50.4 Gy
together with fluoropyrimidine-based chemotherapy) for
the treatment of all patients with Union for International
Cancer Control (UICC) stage II or III rectal cancer [6, 7].
Multimodal treatment strategies including neoadjuvant
chemoradiotherapy have contributed to reduce rates of
local recurrence in cases of nodal-positive disease or an
advanced T stage. However, neither neoadjuvant radiation
nor neoadjuvant chemoradiotherapy was able to improve
overall survival, which is the ultimate goal of any cancer-
directed therapy [8–10]. This led to different approaches
in the recent use of neoadjuvant chemoradiotherapy.
While some clinicians favored a more selective indication
for neoadjuvant chemoradiotherapy, e.g., based on pre-
operative radiologic assessment of the circumferential
resection margin [11–13], others started to exert and
investigate more effective chemotherapeutic agents in the
setting of preoperative chemoradiotherapy [14, 15]. This
second approach aims at reducing rates of not only local
recurrence but also distant recurrence, which remain
at a high level of up to 30% after curative resection
of advanced rectal cancer.
Oxaliplatin is one of these chemotherapeutic agents,
which has proven to be effective in the palliative and adju-
vant setting of colorectal cancer by improving progression-
free or disease-free survival, respectively [16, 17]. Thus, the
addition of oxaliplatin to fluoropyrimidine-based neoadju-
vant chemoradiotherapy holds the potential of positively
affecting survival in the neoadjuvant context [18]. However,
especially in the light of rising numbers of long-term rectal
cancer survivors, the impact of such intensified chemother-
apeutic regimens on quality of life and long-term toxicities
have to be taken into account in the evaluation of its bene-
fits. Several phase I trials have shown feasibility and accept-
able toxicity of this chemotherapeutic regimen [19, 20].
Furthermore, short-term surrogate outcome parameters
such as pathological response rate were improved by the
combination of oxaliplatin and fluoropyrimidine in phase
II trials [21–23]. Therefore, several large, multicenter phase
III trials addressed clinical efficacy of this therapeutic
concept during the last decade [15, 24, 25] and long-term
clinical results have been recently published [14, 26, 27].
One previous systematic review on this topic has eval-
uated short-term results of four clinical trials evaluating
neoadjuvant chemoradiotherapy with fluoropyrimidine
alone or in combination with oxaliplatin in locally ad-
vanced rectal cancer [28]. The primary outcome evalu-
ated was pathologic complete response, which may be
considered a surrogate efficacy endpoint only, and previ-
ous research has shown that it does not reliably predict
long-term outcome [29]. Furthermore, a recent Cochrane
review also only evaluated short-term results of the same
four trials and qualitatively analyzed the long-term results
of one of the trials [30]. With the recent publication of 3-
to 5-year overall and disease-free survival outcomes for
several trials [14, 26, 27], a well-conducted systematic
review and meta-analysis of the evidence, with survival as
primary outcome, has the potential to change current
treatment paradigms in Germany and internationally.
Thus, the main objective of this systematic review is
to assess the efficacy, safety, and quality of life result-
ing from adding a platinum derivative to neoadjuvant
single-agent fluoropyrimidine-based chemoradiotherapy
in patients with UICC stage II and III rectal cancer.
Methods/design
The review protocol has been registered prospectively in
PROSPERO (Registration number PROSPERO 2017:
CRD42017073064) and was prepared according to the
PRISMA-P statement [31], with a checklist included as
Additional file 1. This systematic review and meta-analysis
is funded by the German Federal Ministry of Education
and Research (www.bmbf.de, project number: 01KG1710).
Systematic literature search
A systematic literature search will be performed using the
validated methods of the Cochrane Collaboration [32]. All
stages of study selection, quality assessment, and data
extraction will independently be carried out by two
reviewers to minimize errors. Any disagreement will be
resolved by consensus or by consulting a third reviewer.
The following electronic bibliographic databases will
be searched: MEDLINE, Web of Science, and Cochrane
Central Register of Controlled Trials (CENTRAL). Ref-
erence lists of relevant articles and related systematic
reviews will be hand-searched. Clinical trial registries
(www.clinicaltrials.gov, www.clinicaltrialsregister.eu, etc.)
will be searched for ongoing or unpublished trials.
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The PICO (participants, interventions, comparisons,
and outcomes) model was used to formulate the research
question [32]. Table 1 shows the PICO question together
with the search strategy for MEDLINE (via PubMed),
which was built using a combination of index or free text
words and MeSH terms. The search strategies for other
databases were constructed correspondingly. No language
or other restrictions including date of publication will be
applied.
Following eligibility assessment of the combined search
results from all databases, the eligible articles will be com-
plemented searching the Science Citation Index (via Web
of Science) for publications that cite trials eligible for
inclusion.
We expect to include between four and ten eligible
randomized controlled trials (RCTs), with several publi-
cations describing results for each trial. A minimum
number of four RCTs have been identified by the pre-
ceding systematic review by An et al. [28], and at least
one additional trial has been identified by our preliminary
literature search [26] (Table 2).
Study selection
Two reviewers will screen all titles and abstracts that
have been retrieved by the systematic literature search
independently. Retrieved references will be stored in a
file of the reference management software EndNote™.
Duplicates will be removed, and all other references will
be put into specific folders (inclusion, exclusion with rea-
son, etc.) after screening. The full-text manuscript of all
trials that are potentially eligible will be acquired and
subsequently evaluated in detail. Eligibility will be
assessed based on the following criteria:
1. Population: patients with histologically confirmed
adenocarcinoma of the rectum, UICC stage II/III
disease, and locally resectable disease
2. Intervention: neoadjuvant fluoropyrimidine-based
chemoradiotherapy with the addition of a
platinum derivative; trials evaluating neoadjuvant
chemoradiotherapy with any other combined
regimen (e.g., irinotecan, monoclonal antibodies)
or neoadjuvant chemoradiotherapy followed by
neoadjuvant chemotherapy before surgery will be
excluded.
3. Comparator: fluoropyrimidine-based single-agent
neoadjuvant chemoradiotherapy; trials assessing
neoadjuvant radiation without chemotherapy will be
excluded.
4. Outcomes: trials providing data on at least one of
the following outcomes will be included:
a. Primary outcome parameters: overall survival and
disease-free survival
b. Secondary outcome parameters: local recurrence
rate, distant recurrence rate, and rate of pathological
complete response; toxicity; postoperative morbidity
and mortality; rate of anastomotic leakage; treatment
compliance; and quality of life (QoL).
5. Design of primary studies: RCTs; all non-
randomized studies will be excluded.
In case of multiple publications on the same clinical
trial, data with the longest follow-up will be used for
each outcome. If available, the evidence will be supple-
mented by unpublished data as a separate subgroup.
The study selection process will be documented by a
PRISMA flow diagram giving specific reasons for exclusion
of studies at each stage.
Data extraction
Data will be extracted from the trials that meet our final
inclusion criteria using a standardized, electronic data
extraction form. Two reviewers will independently ex-
tract data using the standardized form, and extracted
data will be compared between the two extracting re-
viewers. Any queries/discrepancies will be resolved by
consultation of a third party. The following trial charac-
teristics and outcomes will be extracted:
1. Design and reporting features: first author, year of
publication, location of trial conduct, journal,
publication language, details of trial design
(treatment arms, superiority/non-inferiority design,
etc.), duration of the trial, number of trial centers
Table 1 PICO question and search strategy for MEDLINE (via PubMed)
P Patients with stage II/III rectal cancer
I Neoadjuvant chemoradiotherapy with a platinum derivative added to fluoropyrimidine
C Neoadjuvant chemoradiotherapy with a single-agent fluoropyrimidine
O Overall survival, disease-free survival
(neoadjuvant [tw] OR neo-adjuvant [tw] OR preoperative [tw] OR pre-operative [tw] OR “Neoadjuvant Therapy” [MeSH]) AND carboplatin* [tw] OR
oxaliplatin* [tw] OR cisplatin* [tw] OR platin* [tw] OR “Carboplatin” [MeSH] OR “Cisplatin” [MeSH] OR “Organoplatinum Compounds” [MeSH] AND
((adenocarcinom* [tw] OR carcinom* [tw] OR cancer [tw] OR malignant growth [tw] OR tumor [tw] OR tumour [tw]) AND (rectum [tw] OR rectal [tw]
OR rectum [MeSH])) OR rectal neoplasms [MeSH] AND random* [tw] OR randomized controlled trial [pt] OR RCT [tw] OR “Randomized Controlled Tri-
als as Topic” [MeSH] OR controlled clinical trial [pt] OR clinical trials as topic [mesh: noexp] OR controlled trial [tw] OR clinical trial [tw] OR controlled
study [tw] OR control group [tw] OR “Control Groups” [MeSH])
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(single-center/multicenter), sample size calculation
(yes/no/not stated; α, β, and δ in %), follow-up time
(in months/not stated), and trial registration
2. Quality features: according to the Cochrane Risk of
Bias Tool (see section “Qualitative analysis” below)
3. Patient characteristics: mean age, gender
distribution, oncologic performance scale (WHO
scale, ECOG scale, Karnofsky index, etc.), UICC
stage, TNM stage, and height of the tumor
4. Treatment characteristics: details of
chemotherapeutic regimen, dosage and fractions of
radiation, details of surgery (low anterior resection;
abdominoperineal extirpation; laparoscopic/open),
period between the end of radiation and day of
surgery (weeks), and details of adjuvant treatment
5. Outcomes: overall survival, disease-free survival,
local recurrence rate, distant recurrence rate, rate of
pathological complete response, treatment toxicity,
postoperative morbidity and mortality, rate of
anastomotic leakage, treatment compliance, and QoL
In case of missing information or ambiguities in the
publications of individual trials, the trial authors will be
contacted to retrieve additional information.
Endpoints of the systematic review
The main endpoints of the current systematic review will
be survival assessed as overall and disease-free survival. The
ultimate goal of cancer treatment is to prolong overall sur-
vival. However, for colorectal cancer, disease-free survival
has been shown to correlate well with overall survival [33].
Furthermore, Glynne-Jones et al. have recently assessed
that disease-free survival represents the best outcome
parameter for phase III clinical trials in rectal cancer [29].
The patient relevance of this outcome is obviously high.
Secondary endpoints will include rates of local and
distant recurrence and pathological complete response
rate as surrogate parameters for efficacy of the different
strategies. Furthermore, treatment toxicity, postoperative
morbidity, and mortality including anastomotic leakage
will be assessed for evaluation of safety. Treatment
compliance will be evaluated to assess feasibility of the dif-
ferent treatment protocols. Finally, quality of life will be
evaluated as a patient-oriented outcome parameter to
judge the tolerability of the different therapeutic strategies.
If differing definitions of the endpoints stated above
are used in individual trials, this will be reported and
potential implications for the results will be discussed.
During the planning phase of the current systematic
review, several representatives of patient organizations
(German ILCO e.V., various local groups) have been
contacted and responded that survival, quality of life,
and treatment toxicities would be of utmost importance
from a patient’s perspective.
Qualitative assessment of included trials
Risk of bias in included RCTs will be analyzed using the
Cochrane Collaboration’s tool for assessing the risk of bias
in randomized trials [34]. Two reviewers will independ-
ently assess risk of bias of each trial. Disagreements will
be resolved by discussion or by consulting a third re-
viewer. Each of the following domains will be evaluated at
study level: random sequence generation, allocation con-
cealment, blinding of participants and personnel, blinding
of outcome assessment, incomplete outcome data, select-
ive outcome reporting, and other bias (e.g., baseline imbal-
ance, surgical experience, early termination of the trial,
funding bias, and deficiencies of the statistical analysis)
[35]. Each potential source of bias will be graded as high,
low, or unclear, and a quote from the study report
together with a justification for the judgment will be
presented in the risk of bias table.
The quality assessment results will directly be used
to grade the body of evidence at outcome level. This
will be done using the GRADE system [36]. The fol-
lowing issues will be considered in analogy to current
publishing recommendations: study quality/risk of
bias, consistency of results between studies, directness
of evidence/generalizability, and magnitude of the
effect.
Statistical analysis
For time-to-event outcomes (primary outcomes), the
hazard ratio (HR) with its 95% confidence interval will
be chosen as an effect measure per trial. If possible, log
HRs and their standard errors will be extracted directly,
preferably from an adjusted model. If they are not
reported but adequate univariate analyses are available,
an indirect estimation method will be used [37, 38]. For
dichotomous outcomes (all but one secondary outcome),
the odds ratio (OR) with its 95% confidence interval will
be used as the effect measure per trial; for the ordinal out-
come QoL, the (standardized) mean difference ((S)MD)
with its 95% confidence interval will be used. HRs and
(S)MDs will be combined using the generic inverse-
variance method in a meta-analysis, and ORs will be
pooled using the Peto method. Random-effects models
Table 2 Trials already known about at the start of review
Trial acronym First author Country Trial period
STAR-01 Aschele C. [24] Italy 11/2003–08/2008
ACCORD 12/0405
PRODIGE 2
Gerard J. P.
[14, 25]
France 11/2005–07/2008
NSABP R-04 Allegra C. [44] USA 07/2004–08/2010
CAO/ARO/AIO-04 Rödel C. [15, 27] Germany 07/2006–02/2010
n.a. Jiao D. [26] China 07/2007–07/2010
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will be used to calculate overall effect estimates and confi-
dence intervals because we assume the heterogeneity be-
tween the true effects of the included trials. Nevertheless,
results of fixed-effect models will be contrasted with those
of the random-effects models and discussed. All results
will be investigated for statistical heterogeneity by I2 statis-
tics. If there is considerable heterogeneity (I2 > 75%) for an
outcome, no meta-analysis will be done [32]. If possible,
the following subgroup analyses will be done for the main
endpoints to further investigate potential heterogeneity:
stage II vs. stage III rectal cancer and adjuvant vs. no
adjuvant treatment. Statistical investigation of a potential
publication bias based on a test of funnel plot asymmetry
will be done if there is a sufficient amount of RCTs (> 10)
available for analysis. Nevertheless, sensitivity analyses will
be performed with respect to study quality as well as
for different dosages and application methods (e.g., 5-
fluorouracil vs. capecitabine). Further sensitivity analyses
may be conducted during the course of the review, if indi-
vidual peculiarities of the included trials become apparent.
A power calculation according to Jackson and Turner will
be performed [39]. All results will be reported following
the PRISMA guidelines [40]. Tables for the summary of
findings will be set up according to the Cochrane recom-
mendations. Forest plots will present meta-analysis results
graphically. R version 3.2.2 or higher [41] and the R meta
package version 4.3-2 or higher (developed by Guido
Schwarzer) will be used for all statistical analyses.
Discussion
The proposed systematic review and meta-analysis will
condense the highest level of evidence on the strategy of
adding a platinum derivative to 5-fluorouracil (5-FU)-
based chemoradiotherapy. In order to maximize the
quality of the pooled results, only RCTs will be included,
since they represent the study type with the lowest risk
of bias. Furthermore, strict quality assessment according
to the Cochrane Risk of Bias Tool [34] will be performed
and the resulting evidence and recommendations will be
judged according to the GRADE recommendations [36].
This will allow for reliable recommendations for clinical
practice and future research.
Instead of assessing a specific chemotherapeutic proto-
col, the two strategies will be assessed in a pragmatic ap-
proach considering all types of single-agent 5-FU-based
chemoradiotherapy to all combined protocols including a
platinum derivative. The wide patient selection criteria of
all patients with locally advanced rectal cancer (UICC
stage II or III disease) will allow for better generalizability
and representativeness of the results.
Apart from the main survival endpoints, treatment tox-
icity and operative morbidity will be evaluated to judge
the safety of the different treatment strategies. Treatment
toxicity of intensified chemotherapeutic protocols is of
high patient relevance and is of utmost importance for the
assessment of comprehensive applicability of such proto-
cols. Furthermore, it has been shown that neoadjuvant
treatment has a direct influence on postoperative mor-
bidity and complications such as anastomotic leakage
[42, 43]. Therefore, these endpoints have to be evalu-
ated in an attempt to appraise the different treatment
concepts comprehensively. On the basis of the results
for the efficacy endpoints (survival) on the one hand
and the safety endpoints (toxicity/postoperative mor-
bidity) on the other hand, a risk/benefit assessment of
the different treatment strategies will be performed.
Finally, QoL will be assessed as a key patient-oriented
outcome in addition to the abovementioned endpoints
to judge the two strategies by a patient’s perspective.
The findings of this systematic review and meta-analysis
will thus provide a broad picture of the clinical topic and
may form a basis for future clinical decision-making,
guideline evaluation, and research prioritization.
Additional file
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